AN2 Therapeutics Inc. (ANTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    AN2 Therapeutics Inc.

    NASDAQ: ANTX · Real-Time Price · USD
    1.21
    -0.05 (-3.97%)
    At close: Sep 05, 2025, 12:45 PM

    AN2 Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a 77K n/a
    Gross Profit
    		 n/a n/a -77K n/a
    Operating Income
    		 -54.55M -69.64M -42.26M -21.57M
    Interest Income
    		 5.47M n/a 1.35M 69K
    Pretax Income
    		 -51.32M -64.73M -40.96M -21.54M
    Net Income
    		 -51.32M -64.73M -40.96M -21.54M
    Selling & General & Admin
    		 14.07M 14.76M 12.75M 4.67M
    Research & Development
    		 40.49M 54.87M 29.51M 16.91M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 54.55M 69.64M 42.26M 21.57M
    Interest Expense
    		 n/a n/a 514K n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 54.55M 69.64M 42.26M 21.57M
    Income Tax Expense
    		 n/a n/a n/a -69K
    Shares Outstanding (Basic)
    		 29.83M 23.6M 15.34M 18.74M
    Shares Outstanding (Diluted)
    		 29.83M 23.6M 15.34M 18.74M
    EPS (Basic)
    		 -1.72 -2.74 -2.79 -1.5
    EPS (Diluted)
    		 -1.72 -2.74 -2.79 -1.5
    EBITDA
    		 -51.32M 4.9M -40.88M -21.57M
    EBIT
    		 -51.32M -64.73M -40.96M -21.54M
    Depreciation & Amortization
    		 54.55M 69.64M 77K 21.57M

    Add to Watchlist